1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8
Market cap: $155.0M (2/08/2026)
Price: $1.82
CARDAMYST™: First FDA-Approved, Self-Administered Treatment for PSVT
Other Events
Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Receives FDA Approval of CARDAMYST™
Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
Q3
Q2
Q1
FY 2024
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload